| Autor: |
Siew C Ng, Ye Peng, Lin Zhang, Chris KP Mok, Shilin Zhao, Amy Li, Jessica YL Ching, Yingzhi Liu, Shuai Yan, Dream L S Chan, Jie Zhu, Chunke Chen, Adrian CH Fung, Kenneth KY Wong, David SC Hui, Francis KL Chan, Hein M Tun |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Gut. 71(6) |
| ISSN: |
1468-3288 |
| Popis: |
ObjectiveThe gut microbiota plays a key role in modulating host immune response. We conducted a prospective, observational study to examine gut microbiota composition in association with immune responses and adverse events in adults who have received the inactivated vaccine (CoronaVac; Sinovac) or the mRNA vaccine (BNT162b2; BioNTech; Comirnaty).DesignWe performed shotgun metagenomic sequencing in stool samples of 138 COVID-19 vaccinees (37 CoronaVac and 101 BNT162b2 vaccinees) collected at baseline and 1 month after second dose of vaccination. Immune markers were measured by SARS-CoV-2 surrogate virus neutralisation test and spike receptor-binding domain IgG ELISA.ResultsWe found a significantly lower immune response in recipients of CoronaVac than BNT162b2 vaccines (pBifidobacterium adolescentiswas persistently higher in subjects with high neutralising antibodies to CoronaVac vaccine (p=0.023) and their baseline gut microbiome was enriched in pathways related to carbohydrate metabolism (linear discriminant analysis (LDA) scores >2 and pRoseburia faecis(p=0.028). The abundance ofPrevotella copriand twoMegamonasspecies were enriched in individuals with fewer adverse events following either of the vaccines indicating that these bacteria may play an anti-inflammatory role in host immune response (LDA scores>3 and pConclusionOur study has identified specific gut microbiota markers in association with improved immune response and reduced adverse events following COVID-19 vaccines. Microbiota-targeted interventions have the potential to complement effectiveness of COVID-19 vaccines. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
